In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Max Planck Institute of Biochemistry

Division of Max Planck Society

Latest From Max Planck Institute of Biochemistry

SuppreMol GMBH

SuppreMol GMBH is developing a recombinant version of human Fcy receptor FcyRIIb, now in Phase IIa for SLE. This candidate competes with membrane-bound Fcy receptors on immune cells, preventing binding of immune complexes containing autoantigens and inhibiting re-stimulation of immune cells. This down-regulates the B cells specifically involved in the autoimmune response, but does not affect B cells that are part of the normal immune response.

European Biotechnology--A Question of Control

European biotech companies have only partnered a third of the development drugs in their collective pipelines. With product-hungry Big Pharma prepared to pay ever-higher prices to in-license, much of the European biotech industry is in a strong position.
BioPharmaceutical Europe

Virgene AG

Virgene's goal is to find out where in the signal transduction system pathogenic agents effect programming changes occur and to develop new anti-viral drugs.

Germany's Biotech Boomlet

A teutonic wave of biotech start-ups is gathering, fed by government money, new venture funds and a handful of academics. But given the cultural and managerial obstacles, it's not certain that this wave will have the energy to reach the shore.
BioPharmaceutical Europe
See All